Table 6.
Comparison of empirical Bayes estimates of pharmacokinetic parameters between microemulsion and long-chain triglyceride emulsion (LCT) propofol
| Parameter | Microemusion propofol | LCT propofol | Ratio*(%) | 90% CI* |
|---|---|---|---|---|
| V1 (L) | 4.49 ± 0.85 | 3.72 ± 0.67 | 120.74 | 112.24–129.23 |
| V2 (L) | 7.19 ± 1.60 | 6.29 ± 2.09 | 114.14 | 101.27–127.01 |
| V3 (L) | 46.10 ± 31.27 | 41.03 ± 17.55 | 112.35 | 85.19–139.50 |
| Vdss (L) | 57.78 ± 30.93 | 51.05 ± 18.50 | 113.18 | 91.24–135.12 |
| Cl (L·min−1) | 0.61 ± 0.10 | 0.54 ± 0.07 | 112.31 | 105.50–119.11 |
| Q2 (L·min−1) | 0.21 ± 0.05 | 0.17 ± 0.06 | 119.66 | 106.16–133.16 |
| Q3 (L·min−1) | 0.14 ± 0.07 | 0.12 ± 0.05 | 124.45 | 100.54–148.36 |
| t1/2α (min) | 3.16 ± 0.40 | 3.05 ± 0.40 | 103.76 | 98.12–109.40 |
| t1/2β (min) | 32.09 ± 4.16 | 32.74 ± 3.29 | 98.00 | 93.84–102.17 |
| t1/2γ (min) | 282.17 ± 102.44 | 314.07 ± 82.21 | 89.84 | 76.92–102.76 |
*
Based on an analysis of variance with a linear mixed effects model that contained effects for sequence, subject nested within sequence, period and formulation.
Data are expressed as mean ± SD (n= 30, each formulation), which are arithmetic means and SD of empirical Bayes estimates of pharmacokinetic parameters.
CI, confidence interval.